Leaders in Pharmaceutical Business Intelligence (LPBI) Group

11:45 am – 1:30 pm, 3/26/2015,  LIVE – The MassBio Annual Awards Luncheon @ MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, 3/26 – 3/27, 2015

Reporter: Aviva Lev-Ari, PhD, RN

 

Dr. Aviva Lev-Ari will be in attendance on March 26, 2015, 8:00AM to March 27, 2015, 2:00PM

Leaders in Pharmaceutical Business Intelligence are Covering the Event in REALTIME using Social Media

http://pharmaceuticalintelligence.com

#MassBioForum#Massachusetts#Boston#biotech #vc #venturecapital #pharmanews

@MassBio@BostonBizJournl@BioWorld@bioitworld @BiotechNews @PharmaNews

• 900 jobs in Biotech on the website of MassBio — UNFILLED

• Henri A. Termeer Innovative Leadership Award – Presented to Mark Levin, Partner, Third Rock Ventures

In the 80s & 90s — Culture of Innovations in Silicon Valley vs Route 128

Today — Silicon Valley migrated to Cambridge in particular with Mark Levin

2007 Mark Levin raised $300Millions for Third Rock Ventures

• Foundation to teach entrepreneurship
• On 30th Anniversary of MasssBio -14threcepient of –
  • Henri A. Termeer Innovative Leadership Award – Presented to Mark Levin, Partner, Third Rock Ventures

Mark Levin, Partner, Third Rock Ventures

Mark Levin is a co-founder of Third Rock Ventures and an industry leader with 40 years of experience,  including more than 30 years launching and building biotechnology companies. Mark focuses on the formation, development and business strategy of our portfolio companies, as well as actively identifying and  evaluating new investments. He runs our discovery process to conceive and launch companies around disruptive technologies and innovative science that promise to dramatically improve patients’ lives. He has  played significant roles in launching and building a number of our portfolio companies.

Prior to Third Rock, Mark was co-founder of Mayfield Fund’s life sciences effort, where he was also the founding chief executive officer of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals.

Mark served as chief executive officer of Millennium Pharmaceuticals for 12 years. Earlier in his career, he was an engineer and project leader at Lilly and Genentech. Mark holds an M.S. in chemical and biochemical engineering from Washington University.

LIVE PRESENTATION

Congratulations to MassBio on 30th Anniversary – MA is #1 in the World, not SF!!

MA kicking Ass of CA

Great honor to be with Past Award recipients

Thank to the Team at Millenium

at Third Rock: Great Team – Great people — with great people you can do it all!!

My Award was earned by all the my colleagues

My Personal Perspective:

Genetic 1980 in SF – Biotech, Bill Young was already at Genentech

• 1985 in Biotech – making protein, 3.4 Billion total R&D market. Human Growth Hormone and Insulin was on th e market, Head of Vaccine Team, Interferon, Relaxen — NONE of the three worked – revolution, Genentech to focus on Oncology. (Growth Hormone was pull off the market by FDA, when human pituitary is the source it caused JK and death)
• 1990 gene therapy started – Boston was a SLEEPY town, faculty not knowledgeable
• Today Biotech – 2015
• Failures: in AIDS, in Antibodies,
• BIOTECH SUPPLIES 60%-70% OF ALL DRUGS approved by FDA
• Gene Therapies works and antibodies works
• BOSTON IS THE LEADER OF THE WORLD: great VCs today
• Silicon Valley VC are pulling from BioTech
• Boston – VCs focusing on Biotech
• system biology, sequencing — used in DIagnostics and in Devices
• Future of Biotech
• Retain the people continue to build
• revolution in HealthCare Innovations and knowledge — while reducing costs
• In born in 2014: All sequences library will be in place
• See you MD – Patient will be followed from birth to death by his/her Genome
• Digital wearable devices – monitoring all biological processes in the Human
• Cancer furthet along,
• Gene Editing – Cas9 — deliver therapy to cell type and repair the gene transcription
• rejuvenation field – blood transfusion
• MassBio in 30 Year: How to make MA  work with CA and with China — Global set of knowledge vs State
• Big World — requires all efforts combined for Health Issues

Mark Levin Ideas:

• Empathy with Patients
• Venture Industry – many are driven by $$ — Focus on the Patient, the rest will follow
• No humility in Genentech – it was good for Genentech
• We need Humility, future scenarios are need
• right people and right time
• Scientist, Dir of Facilities CEO — all are critical
• Stopping generic  concerned of Pharma, Biotech need the super vision
• Diversity is critical: VC did not do well since 1985, No diversity there, young and older, all colors, integration of ideas women into management team

My big concept: VALUE for the PATIENT per $ SPENT – the outcome – i.e., Cancer breakthrough

• drug of $100,000 for 3 month extension – need for combination drugs
• Personalized Medicine in CVD: Treat the Gene not the vessels or the heart
• Gene editing: Clinical Trial need become affordable
• Integrated product: Diagnostics, drugs, devices
• World is changing – Work together

 STANDING OVATION for 3 minutes !!

• Joshua Boger Innovative School of the Year Award

Award offered to Barnstable High School presented by Genzyme

LIVE PRESENTATION

Beth Aronson & Valerie Lahteine, Teacher of Sciences and Biology at Barnstable High School

• Students Presentation

1. Sabrina – Lab classes using pipetting, plans to major in Bioengineering
2. Ben – classes in biotechnology, forensic pathology course, Premed is my plan

• Leading Impact Award – 2015 MassBio given to Michael F. Collins, Chancellor of the MA Medical School

Introduction by Mark Bamforth, Brammer Biopharmaceuticals

Recepient on behalf of the Chancellor, Brendan O’Reary, Exec, Vice Chancellor, Innovation & Development, UMass Medical School

• Effort by UMASS to make UMass the LEADER IN BIOTECH AND LIFE SCIENCES in MA
• Investment of $2Billion across all Campuses in MA
• New era in Biotech